When incorporated into the multivariate model, we identified 7 factors that independently predicted survival: age (≥65yrs vs <65yrs; HR=1.63), ECOG performance status (2-4 vs. 0-1; HR=1.86), cytogenetics (-7 and/or complex vs others; HR=2.47), WHO MDS subtype (RARs, RAEB-1/2 vs others; HR=1.92), hemoglobin (<11g/dL vs ≥11.0 g/dL; HR=2.24), platelets (<50 vs ≥50; HR=2.01), and transfusion dependency (yes vs no; HR=1.59). These factors were then used to create a prognostic model that segregates patients into 3 discreet prognostic groups: good (n=57, 21%; 0-2 risk factors; median survival 34 months), intermediate (n=154, 57%; 3-4 risk factors; median survival 12 months) and poor (n=61, 22%; 5-7 risk factors; median survival 5 months) (Figure 1A). This model also predicted 1-year leukemia free survival (good: 96%, intermediate: 84%, and poor: 72%; p=0.001). This model was subsequently validated in a test group of 189 patients with t-MDS diagnosed between 2008 and 2010. The median survival rates for low, intermediate, and poor risk patients in this group were: 26, 13, and 7 months (p<0.001) (Figure 1B).

The apps originated in the Palmdoc Chronicles’ Medwebapp section where you can check them out before I migrate them here

Palmdoc